Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

The FDA Warning on Antidepressants and Suicidality — Why the Controversy? | Synapse

October 29, 2014Open Access

Ver artículo completo

The FDA Warning on Antidepressants and Suicidality — Why the Controversy?

MSMarc B. StoneCenter for Drug Evaluation and Research

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Since the 2004 FDA decision to require a boxed warning on antidepressants regarding the risk of suicidality in children and adolescents, people who feared adverse consequences of that decision have found support for their view in various seriously flawed studies.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Marc B. Stone (Wed,) studied this question.

synapsesocial.com/papers/6a1eb9115dae381e029a82ee https://doi.org/https://doi.org/10.1056/nejmp1411138

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Antidepressants' Black-Box Warning — 10 Years Later2014 · 179 citations
2Relationship between leukotriene-modifying agent prescriptions dispensed and rate of suicide deaths by county in the US2011 · 15 citations
3Spillover Effects on Treatment of Adult Depression in Primary Care After FDA Advisory on Risk of Pediatric Suicidality With SSRIs2007 · 139 citations
4Frequency of Provider Contact After FDA Advisory on Risk of Pediatric Suicidality With SSRIs2007 · 100 citations
5Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study2014 · 232 citations